SpringerPlus

Table 3 Invasive hemodynamic measurements

From: Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation

	Baseline			Sacrifice
	Sham (n = 8)	AR (n = 8)	AR + SIL (n = 8)	Sham (n = 6)	AR (n = 4)	AR + SIL (n = 4)	p value
(A) Early treatment group
HR	318 ± 14	316 ± 8	324 ± 18	355 ± 11	324 ± 8	333 ± 15	0.97
Systolic BP	133 ± 7	134 ± 6	134 ± 11	140 ± 4	140 ± 10	131 ± 8	1.00
Diastolic BP	90 ± 4	91 ± 4	98 ± 5	92 ± 2	78 ± 7	78 ± 2	0.57
PP	42 ± 10	46 ± 10	35 ± 11	47 ± 6	62 ± 7	53 ± 7	1.00
dp/dtmax	8243 ± 280	8841 ± 220	8645 ± 301	8150 ± 204	7440 ± 317	7864 ± 290	0.96
dp/dtmin (−)	6960 ± 318	7620 ± 240	7944 ± 421	7165 ± 461	5446 ± 432	5904 ± 617	1.00
LVESP	131 ± 10	137 ± 8	131 ± 11	129 ± 9	125 ± 12	126 ± 13	0.26
LVEDP	9.1 ± 1.3	8.1 ± 2.0	8.3 ± 1.2	8.1 ± 1.9	5.7 ± 2.4	9.8 ± 4.6	0.96
Tau	12.4 ± 0.7	12.4 ± 0.7	12.1 ± 0.6	13.8 ± 1.1	11.1 ± 2.1	13.3 ± 2.6	0.81

	Baseline			Sacrifice
	AR (n = 5)	AR + SIL (n = 6)	AR (n = 5)	AR + SIL (n = 6)	p value
(B) Late treatment group
HR	296 ± 12	269 ± 12	235 ± 6	267 ± 10	0.02*
Systolic BP	117 ± 3	115 ± 4	131 ± 6	128 ± 3	0.98
Diastolic BP	85 ± 2	82 ± 3	65 ± 3	82 ± 2	0.03*
PP	31 ± 2	33 ± 2	66 ± 7	46 ± 4	0.05*
dp/dtmax	7600 ± 225	7810 ± 339	6473 ± 386	8211 ± 203	0.44
dp/dtmin (−)	6836 ± 552	6893 ± 499	7120 ± 1474	6443 ± 556	0.25
LVESP	104 ± 10	110 ± 7	148 ± 4	125 ± 9	0.29
LVEDP	4.9 ± 0.4	4.4 ± 1.0	7.2 ± 0.5	8.5 ± 2.9	0.35
Tau	10.2 ± 0.7	10.1 ± 0.3	18.2 ± 1.5	10.6 ± 0.3	0.03*

Early treated groups (panel A) and late treated groups (panel B) at baseline (left) and at sacrifice (right). p values are from paired analysis between AR and AR+SIL

Back to article page